Kardigan Inc（KARD）の株式分析KARDKardigan Inc

Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform. It operates in the Healthcare sector.

Kardigan Inc is not a good buy right now due to its current price of $20.02, which is significantly below the analyst price target of $46, but the company has reported substantial net losses, including $116.236 million in Q2 2026. The RSI is at 37.123, indicating potential weakness in momentum, and the stock has seen a 4.76% decline over the past 5 days, suggesting a bearish trend.